The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‑1 antibody suppresses the progression of non‑small cell lung cancer tumors by enhancing immunocompetence.

In the tumor-associated macrophages (TAMs), although the anti-PD-1 + anti-TNFR2 group, the anti-PD-1 + anti-PTP1B group and the triple therapy group exhibited an increasing trend, the proportion of M1 TAMs in the PBS group, the anti-PD-1 group and the anti-PD-1 + anti-TNFR2 group was lower compared with that in the triple therapy group.

also in 63,971 other papers